Stockreport

BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari [Yahoo! Finance]

Travere Therapeutics, Inc.  (TVTX) 
PDF price target on Travere Therapeutics to $43 from $47, while keeping a Buy rating. Following a three-month extension of the FDA's review for Filspari's use in FSGS, the n [Read more]